Sana Belkahla

Sana Belkahla

Auto-generated profile, based on publicly available information

Sana Belkahla

IRMB, INSERM, Univ Montpellier, Montpellier, France

Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2016 in EBioMedicine
Verified
Journal Article
Open access
AKAbrar Ul Haq Khan
Abrar Ul Haq Khan
MRMoeez G. Rathore
Moeez G. Rathore
NANerea Allende-Vega
Nerea Allende-Vega
DVDang-Nghiem Vo
Dang-Nghiem Vo
SBSana Belkhala
Sana Belkhala
Martin VillalbaMartin Villalba
Martin Villalba
Tumor cell metabolism is altered during leukemogenesis. Cells performing oxidative phosphorylation (OXPHOS) generate reactive oxygen species (ROS) through mitochondrial activity. To limit the deleterious effects of excess ROS, certain gene promoters contain antioxidant response elements (ARE), e.g. the genes NQO-1 and HO-1. ROS induces conformational changes in KEAP1 and releases NRF2, which activates AREs. We show in vitro and in vivo that OXPHOS induces, both in primary leukemic cells and cell lines, de novo expression of NQO-1 and HO-1 and also the MAPK ERK5 and decreases KEAP1 mRNA. ERK5 activates the transcription factor MEF2, which binds to the promoter of the miR-23a-27a-24-2 cluster. Newly generated miR-23a destabilizes KEAP1 mRNA by binding to its 3'UTR. Lower KEAP1 levels increase the basal expression of the NRF2-dependent genes NQO-1 and HO-1. Hence, leukemic cells performing OXPHOS, independently of de novo ROS production, generate an antioxidant response to protect themselves from ROS.

9 May 2018 in Scientific Reports
Verified
Journal Article
Open access
PDF file
AKAbrar Ul Haq Khan
Abrar Ul Haq Khan
NANerea Allende-Vega
Nerea Allende-Vega
DGDelphine Gitenay
Delphine Gitenay
JGJohan Garaude
Johan Garaude
DVDang-Nghiem Vo
Dang-Nghiem Vo
Martin VillalbaMartin Villalba
Martin Villalba
Oxidative phosphorylation (OXPHOS) generates ROS as a byproduct of mitochondrial complex I activity. ROS-detoxifying enzymes are made available through the activation of their antioxidant response elements (ARE) in their gene promoters. NRF2 binds to AREs and induces this anti-oxidant response. We show that cells from multiple origins performing OXPHOS induced NRF2 expression and its transcriptional activity. The NRF2 promoter contains MEF2 binding sites and the MAPK ERK5 induced MEF2-dependent NRF2 expression. Blocking OXPHOS in a mouse model decreased Erk5 and Nrf2 expression. Furthermore, fibroblasts derived from patients with mitochondrial disorders also showed low expression of ERK5 and NRF2 mRNAs. Notably, in cells lacking functional mitochondrial complex I activity OXPHOS did not induce ERK5 expression and failed to generate this anti-oxidant response. Complex I activity induces ERK5 expression through fumarate accumulation. Eukaryotic cells have evolved a genetic program to prevent oxidative stress directly linked to OXPHOS and not requiring ROS.

6 September 2017 in Scientific Reports
Verified
Journal Article
Open access
PDF file
AKAbrar Ul Haq Khan
Abrar Ul Haq Khan
NANerea Allende-Vega
Nerea Allende-Vega
DGDelphine Gitenay
Delphine Gitenay
SGsabine GERBAL-CHALOIN
sabine GERBAL-CHALOIN
CGClaire Gondeau
Claire Gondeau
Martin VillalbaMartin Villalba
Martin Villalba
Controlling cholesterol levels is a major challenge in human health, since hypercholesterolemia can lead to serious cardiovascular disease. Drugs that target carbohydrate metabolism can also modify lipid metabolism and hence cholesterol plasma levels. In this sense, dichloroacetate (DCA), a pyruvate dehydrogenase kinase (PDK) inhibitor, augments usage of the glycolysis-produced pyruvate in the mitochondria increasing oxidative phosphorylation (OXPHOS). In several animal models, DCA decreases plasma cholesterol and triglycerides. Thus, DCA was used in the 70 s to treat diabetes mellitus, hyperlipoproteinemia and hypercholesterolemia with satisfactory results. However, the mechanism of action remained unknown and we describe it here. DCA increases LDLR mRNA and protein levels as well as LDL intake in several cell lines, primary human hepatocytes and two different mouse models. This effect is mediated by transcriptional activation as evidenced by H3 acetylation on lysine 27 on the LDLR promoter. DCA induces expression of the MAPK ERK5 that turns on the transcription factor MEF2. Inhibition of this ERK5/MEF2 pathway by genetic or pharmacological means decreases LDLR expression and LDL intake. In summary, our results indicate that DCA, by inducing OXPHOS, promotes ERK5/MEF2 activation leading to LDLR expression. The ERK5/MEF2 pathway offers an interesting pharmacological target for drug development.

14 December 2017 in Oncotarget
Verified
Journal Article
Open access
PDF file
SBSana Belkahla
Sana Belkahla
AKAbrar Ul Haq Khan
Abrar Ul Haq Khan
DGDelphine Gitenay
Delphine Gitenay
CACatherine Alexia
Catherine Alexia
CGClaire Gondeau
Claire Gondeau
Martin VillalbaMartin Villalba
Martin Villalba
Changes in metabolism affect expression of ABC transporters through ERK5 and depending on p53 status Changes in metabolism affect expression of ABC transporters through ERK5 and depending on p53 status

4 July 2014 in Molecular Biology Reports
Verified
Journal Article
Closed access
PDF file
ASAssila BEN SALEM
Assila BEN SALEM
RARedha Attaoua
Redha Attaoua
NMNabil Mtiraoui
Nabil Mtiraoui
SBSana Belkahla
Sana Belkahla
IEIntissar Ezzidi
Intissar Ezzidi
TMTouhami Mahjoub
Touhami Mahjoub